| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $24,739,344 | 17 | 100 |
| Harmon Cyrus | director | 0 | $0 | 5 | $743,757 | $-743,757 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | 0 | $0 | 2 | $951,503 | $-951,503 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 0 | $0 | 2 | $2.98M | $-2.98M |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 0 | $0 | 4 | $4.66M | $-4.66M |
| Zojwalla Naseem | Chief Medical Officer | 0 | $0 | 3 | $7.53M | $-7.53M |
| CLARK IAN T | director | 0 | $0 | 1 | $7.87M | $-7.87M |
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its …
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $0 and sold $24.74M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $10.3M and sold $19.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300,000 shares for transaction amount of $1.73M was made by Bain Capital Life Sciences Investors, LLC (10 percent owner) on 2025‑01‑08.
| 2026-07-24 | Sale | Harmon Cyrus | director | 12,500 0.0143% | $11.71 | $146,425 | -15.38% | |
| 2026-07-23 | Sale | Harmon Cyrus | director | 12,500 0.0141% | $11.58 | $144,738 | -14.31% | |
| 2026-03-04 | Sale | Mitchell Shawnte | CHIEF LEGAL OFFICER | 25,000 0.0317% | $24.25 | $606,353 | -52.79% | |
| 2026-03-03 | Sale | Mitchell Shawnte | CHIEF LEGAL OFFICER | 15,000 0.0183% | $23.01 | $345,150 | -50.77% | |
| 2026-01-20 | Sale | Harmon Cyrus | director | 10,000 0.0128% | $26.88 | $268,800 | -54.90% | |
| 2026-01-15 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 100,000 0.1433% | $28.73 | $2.87M | -58.62% | |
| 2026-01-14 | Sale | Harmon Cyrus | director | 3,489 0.0051% | $29.12 | $101,600 | -57.80% | |
| 2026-01-14 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 50,000 0.0731% | $28.87 | $1.44M | -57.80% | |
| 2026-01-13 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 50,000 0.0721% | $27.60 | $1.38M | -56.26% | |
| 2026-01-13 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 3,822 0.0056% | $28.01 | $107,054 | -56.26% | |
| 2026-01-12 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 10,000 0.0143% | $28.34 | $283,400 | -57.50% | |
| 2025-12-23 | Sale | Zojwalla Naseem | Chief Medical Officer | 99,509 0.1423% | $27.66 | $2.75M | -53.98% | |
| 2025-12-22 | Sale | Harmon Cyrus | director | 2,881 0.0042% | $28.53 | $82,195 | -54.72% | |
| 2025-12-22 | Sale | Zojwalla Naseem | Chief Medical Officer | 100,000 0.1449% | $28.04 | $2.8M | -54.72% | |
| 2025-12-19 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 51,000 0.081% | $30.46 | $1.55M | -54.30% | |
| 2025-12-19 | Sale | Zojwalla Naseem | Chief Medical Officer | 70,000 0.1029% | $28.20 | $1.97M | -54.30% | |
| 2025-12-19 | Sale | CLARK IAN T | director | 264,800 0.4105% | $29.73 | $7.87M | -54.30% | |
| 2025-09-18 | Sale | Harmon Cyrus | director | 13,086 0.0187% | $8.33 | $108,976 | +59.22% | |
| 2025-09-16 | Sale | Harmon Cyrus | director | 11,914 0.0177% | $8.05 | $95,865 | +71.74% | |
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 300,000 0.395% | $5.76 | $1.73M | -8.09% |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 139727 0.1597% | $1.03M | 2 | 6 | +243.62% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 7800000 8.9145% | $57.33M | 1 | 0 | <0.0001% |
| BVF PARTNERS L P/IL | 4688954 5.359% | $34.46M | 3 | 0 | <0.0001% | |
| Cormorant Asset Management, LP | 3270544 3.7379% | $24.04M | 1 | 0 | <0.0001% | |
| LAMPERT MARK N | 2906659 3.322% | $21.36M | 1 | 0 | <0.0001% | |
| Graham G. Walmsley | director | 1408875 1.6102% | $10.36M | 5 | 3 | <0.0001% |
| Paradigm Biocapital Advisors LP | 10 percent owner | 783118 0.895% | $5.76M | 1 | 1 | +0.94% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 142 | +115.45% | 37M | +53.87% |
| Decreased Positions | 52 | -42.28% | 14M | -21.05% |
| New Positions | 87 | New | 21M | New |
| Sold Out Positions | 13 | Sold Out | 4M | Sold Out |
| Total Postitions | 213 | +73.17% | 91M | +32.82% |
| Bain Capital Life Sciences Investors, Llc | $173,015.00 | 8.66% | 6.84M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $171,757.00 | 8.6% | 6.79M | +30,000 | +0.44% | 2025-09-30 |
| Bvf Inc/Il | $133,880.00 | 6.7% | 5.3M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $119,483.00 | 5.98% | 4.73M | +121,285 | +2.63% | 2025-09-30 |
| Janus Henderson Group Plc | $90,650.00 | 4.54% | 3.59M | +563,065 | +18.63% | 2025-09-30 |
| Deep Track Capital, Lp | $87,726.00 | 4.39% | 3.47M | +27,339 | +0.79% | 2025-09-30 |
| Logos Global Management Lp | $81,120.00 | 4.06% | 3.21M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $80,828.00 | 4.05% | 3.2M | -69,679 | -2.13% | 2025-09-30 |
| Franklin Resources Inc | $76,143.00 | 3.81% | 3.01M | 0 | 0% | 2025-09-30 |
| Woodline Partners Lp | $56,068.00 | 2.81% | 2.22M | -1M | -36.74% | 2025-09-30 |